Table 2.
Summary of the ongoing clinical studies in HCC with MVI.
| Author | Year | N | Treatment | MVI | Results |
|---|---|---|---|---|---|
| Shi et al42 | 2019 | 231 | AR (118) versus NAR (113) | MVI positive group (113) |
AR was superior to LR in both RFS and OS when MVI was positive. (P = 0.001 and 0.001 for RFS and P = 0.009 and 0.002 for OS) Wide margins was superior to narrow margins in both RFS and OS when MVI was positive.(P = 0.006 and 0.010) |
| Liu et al40 | 2018 | 84 | AR (35) versus NAR (49) | All patients were MVI positive |
The 1-year, 2-year and 3-year progression-free survival rate were 80.0%, 62.9%, 51.4% in the AR group and 71.4%, 49.0%, 38.8%, in the NAR group, respectively The 1-year, 2-year and 3-year overall survival rate were 85.7%, 68.6%, 57.1% in the AR group and 79.6%, 53.1%, 42.9% in the NAR group, respectively |
| Wei et al60 | 2018 | 250 | Curative resection | All patients were MVI positive |
The median DFS was longer in the PA-TACE group than in the hepatectomy alone group [17.45 months (95% CI, 11.99–29.14) versus . 9.27 months (95% CI, 6.05–13.70), HR = 0.70 (95% CI, 0.52–0.95), P = 0.020] The median OS was also longer in the PA-TACE group than in the hepatectomy alone group [44.29 months (95% CI 25.99–62.58) versus . 22.37 months (95% CI 10.84–33.91), HR = 0.68 (95% CI 0.48–0.97), P = 0.029] |
| Wang et al51 | 2019 | 1630 | Curative resection | All patients were MVI positive | The OS and DFS rates were significantly different between the postoperative adjuvant TACE group and the operation only group (HR 0.57; 95%CI, 0.48 ~ 0.68, P < 0.00001; HR 0.66; 95%CI, 0.58 ~ 0.74, P < 0.00001) |
| Peng et al76 | 2019 | 260 | Curative hepatectomy | MVI positive (127) and MVI negative (133) | For patients with MVI-positive lesions, the median OS and PFS after combination treatment were longer than those after TACE alone (OS: 17.2 months vs. 12.1 months, P = 0 .02; PFS: 17.0 months vs. 11.0 months, P = 0.02) |
| Wang et al63 | 2018 | 271 | Curative hepatic resection | MVI positive (128) and MVI negative (143) |
Both DFS and OS were longer in the PA-TACE group than in the hepatic resection alone group (5-year DFS, 26.3% vs. 20.7%, P = 0.038; 5-year OS, 73.6% vs. 47.7%, P = 0.005) No differences were noted in DFS and OS among MVI negative patients with or without PA-TACE (5-year DFS, 33.7% vs. 33.0%, P = 0.471; 5-year OS, 84.1% vs. 80.3%, P = 0.523) |
| Chen et al52 | 2019 | 2190 | Curative resection | All patients were MVI positive |
Adjuvant TACE showed better 1-, 3-, and 5-OS rates compared to LR alone. (OR = 0.33, P < 0.001; OR = 0.49, P < 0.001; and OR = 0.59, P < 0.01) Adjuvant TACE showed better 1-, 3-, and 5-DFS compared to LR alone. (OR = 0.45, P < 0.001; OR = 0.50, P < 0.001; and OR = 0.58, P < 0.001) |
| Huang et al65 | 2019 | 49 | Curative resection | All patients were MVI positive | The RFS and OS were both longer in the sorafenib group, and the 3-years RFS rates of the sorafenib group and control group were 56.3% and 24.2% (P = 0.027). And the 3-years OS rates of the sorafenib group and control group were 81.3% and 39.4% (P = 0.006) |
| Zhang et al75 | 2019 | 728 | R0 Curative resection | All patients were MVI positive | OS was significantly better for patients in the PA-sorafenib group than the LR group (1 year, 65% vs. 85%; 3 years, 51% vs. 66%; 5 years, 37% vs. 57%; P = 0.007,). RFS was significantly better for patients in the PA-sorafenib group than the LR group (1 year, 55% vs. 72%; 3 years, 36% vs. 47%; 5 years, 19% vs. 39%; P = 0.001) |
| Sun et al59 | 2015 | 322 | R0 hepatectomy | All patients were MVI positive |
The 1-, 2-, 3-, and 5-year RFS rates were respectively 69.3, 55.5, 46.7, and 35.0% for the PA-TACE group and 47.0, 36.2, 34.1, and 30.3% for the RH group (P = 0.012) The 1-, 2-, 3-, and 5-year OS rates were respectively 94.2, 78.8, 71.5, and 54.0% for the PA-TACE group and 78.9, 62.2, 54.1, and 43.2% for the RH group (P = 0.006) |
MVI microvascular invasion, TACE transcatheter arterial chemoembolization, PA postoperative adjuvant, RFS recurrence free survival, AR anatomic resection, NAR non-anatomic resection, OR odds ratio, CI confidence interval, HR hazard ratio, LR liver resection, RR re-resection, RFA radiofrequency ablation, RT ratio therapy, RH R0 hepatectomy.